Andrea Knapp

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

Bruce D. Cheson, Neil Chua, Greg Dueck et al. · Journal of Clinical Oncology · 2018 · 167 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

Laurie H. Sehn, Maurizio Martelli, Marek Trněný et al. · Journal of Hematology & Oncology · 2020 · 143 citations · Full text

Medicine, Hematology, Oncology +17

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Magdalena Klánová, Mikkel Z. Oestergaard, Marek Trněný et al. · Clinical Cancer Research · 2019 · 72 citations

Life Sciences, Hematology, Immunology +17

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

William Townsend, Wolfgang Hiddemann, Christian Buske et al. · HemaSphere · 2023 · 65 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +10

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn et al. · Blood Advances · 2021 · 57 citations · Full text

Medicine, Oncology, Pharmacotherapy +17